Tags : Kymriah

Novartis’s Kymriah Receives EU Approval

Shots:  Post FDA approval in Aug 2017, Kymriah (tisagenlecleucel, formerly CTL019) receives EU approval for treatment of patients up to 25 years with (r/r), second or later stage in B-cell acute lymphoblastic leukemia (ALL) and with (r/r) diffuse large B-cell lymphoma (DLBCL) The approval is based on two global trials JULIET and ELIANA results: JULIET(N=93): […]Read More